The Valley Desk

Clinical trial reportNature medicinePublished

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

15 of 31 authors shown in byline order.

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Nature medicine
Published
Subject terms
Humans; Multiple Myeloma; Neoplasm, Residual; Dexamethasone; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal; Adult; Aged; Aged, 80 and over; Middle Aged; Female; Male
PubMed ID
39910273
PubMed Central ID
PMC12003169
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal